Adverse reactions to vaccines ‘extremely rare,’ immunization researcher says
Aug 04, 2022
Fernando Caballero misses the way he used to be: happy-go-lucky, the life of the party and the protector of his family. The 67-year-old was active and enjoyed rollerblading in the summer, ice skating in the winter and dancing all year round.
But now, he uses a cane or walker to get around and takes several medications for nerve pain to help manage Guillain-Barré Syndrome (GBS) — a rare neurological disorder he developed after getting the Oxford-AstraZeneca COVID-19 vaccine in early 2021.
He tracks his rehabilitation progress in part by counting how many small dance steps he can do in a row.
“I’ve lost a lot,” Caballero told CBC Toronto in Spanish as his daughter translated. “I just feel very trapped with what I can do now compared to what I was able to do before.”
Toronto Public Health conducted an investigation, which found Caballero developed GBS as a result of the vaccine. It recommended he not get another dose of the vaccine.
Read more: https://www.cbc.ca/news/canada/toronto/covid-guillain-barr%C3%A9-syndrome-vaccine-1.6540309